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Abstract:
Topical capsaicin is believed to alleviate pain by desensitizing the vanilloid receptor 1 (VR1) at the peripheral nerve endings. Here, we report that an upregulation of VR1 expression on myelinated fibers contributes to the antihyperalgesic effect of capsaicin cream in streptozotocin (STZ)-induced diabetic neuropathic pain. Intravenous injection of STZ (200 mg/kg) in mice caused rapid onset of diabetes within 24 h. Thermal and mechanical hyperalgesia developed by 3 days after STZ injection and persisted at all time points tested until 28 days. There was also hyperalgesic response to intraplantar (i.pl.) prostaglandin I 2 (PGI 2 ) agonist-induced nociception in such mice. Application of capsaicin cream dose-dependently reversed the thermal, mechanical and PGI 2 agonist-induced hyperalgesia observed in the diabetic mice. The i.pl. injection of capsaicin solution (0.4 µg/20µl) produced nociceptive biting-licking responses in control mice, and these responses were significantly increased in STZ-induced diabetic mice.
After neonatal capsaicin-treatment, which destroys most unmyelinated C-fibers, the i.pl.
capsaicin-induced biting-licking responses were almost abolished. However, in neonatal capsaicin-treated diabetic mice, the i.pl. capsaicin-induced biting-licking responses reappeared. The i.pl. capsaicin-induced biting-licking responses were blocked by the competitive VR1 antagonist capsazepine. All these results suggest an increase in capsaicin receptor on myelinated fibers due to diabetes. Finally, we confirmed the upregulation of VR1 expression on myelinated primary afferent neurons of diabetic mice by immunohistochemistry. Altogether our results suggest that increased expression of VR1 on myelinated fibers might contribute to the antihyperalgesic effect of topical capsaicin in diabetic neuropathic pain. Painful peripheral neuropathy is one of the most common complications in early stages of diabetes mellitus. The underlying mechanisms for the development of painful peripheral neuropathy in diabetic patients are poorly understood. Hyperglycemia is considered as a major pathogenic factor in the development of peripheral diabetic neuropathy. In experimental animals, local infusion of glucose into dorsal root ganglion (DRG) or sciatic nerve induced profound and rapid mechanical hyperalgesia (Dobretsov et al., 2001 ). It is not clear which types of primary afferents are involved in mediating the diabetic neuropathic pain. Hyperactivity of small diameter C-fibers has been suggested in the development of diabetic neuropathic pain (Chen and Levine 2001) . However, in a recent study the development of hyperalgesia could not be prevented in STZ-induced diabetic rats after the systemic pretreatment with resiniferatoxin, which produces long-lasting desensitization of unmyelinated nociceptive C-fibers (Khan et al., 2002) .
Moreover, ectopic discharges and spontaneous activity were mainly confined to the myelinated A-δ and A-β fibers, but not the C-fibers, in the diabetic rats (Khan et al., 2002) . Thus, the myelinated primary afferent neurons may play an important role in the development of diabetic neuropathic pain.
The vanilloid receptor 1 (VR1) is a ligand-gated cation channel that can be activated by heat, decreased pH or exogenous ligand such as capsaicin (Caterina et al., 1997 Tominaga et al., 1998 . In addition, VR1 can be activated by endogenous fatty acid-derived mediators such as anandamide and N-arachidonyl-dopamine (NADA) (Di Marzo et al., 2002) . The VR1 protein has attracted tremendous attention since it can serve as a molecular integrator of painful stimuli on the primary sensory neurons. Recent findings also suggest its presence in various brain regions including hippocampus, hypothalamus and locus coeruleus (Mezey et al., 2000) . VR1 has also been found in the This article has not been copyedited and formatted. The final version may differ from this version. (Jancso et al., 1977) , those in the CNS are not affected by neonatal capsaicin injection (Mezey et al., 2000) . Although poorly known, the neurotoxic effect of capsaicin is reported due to depletion of nerve growth factors (Otten et al., 1983) . It has been speculated that neonatal capsaicin treatment does not kill VR1-expressing neurons in the brain because these cells do not depend on any neurotrophic factor for survival that capsaicin may deplete (Mezey et al., 2000) . In the periphery, VR1 is mainly expressed on unmyelinated C-fibers with very little presence on the thinly myelinated Aδ-fibers (Caterina et al., 1997) . Nevertheless, VR1 has been recognized as a marker of the nociceptive polymodal C-fibers in the sensory ganglia (Caterina et al., 1997) .
Topical capsaicin is widely used in the clinic to alleviate various painful conditions including diabetic neuropathic pain (The capsaicin Study Group 1991 , Low et al., 1995 .
Capsaicin stimulates the VR1 and initiates a complex cascade of events including neuronal excitation and release of proinflammatory mediators as well as desensitization of the receptor (Caterina et al., 1997; Holzer 1991) . The analgesic action of topical capsaicin in painful diseases is believed to occur through desensitization of the capsaicin receptor VR1 (Jancsó and Jancsó 1949; Holzer 1991; Szallasi and Blumberg 1999) . Thus, it might be speculated that upregulated VR1 expression could contribute to neuropathic pain and hyperalgesia. Indeed, recent works indicate the involvement of vanilloid receptors in the development and maintenance of inflammatory and neuropathic pain (Di Marzo et al., 2002) . Upregulation of VR1 has been indicated for the development of nerve injury-induced neuropathic pain in the rats (Hudson et al., 2001) . Recently, we have also This article has not been copyedited and formatted. The final version may differ from this version. reported that increased expression of VR1 on myelinated, neonatal capsaicin-insensitive fibers accounts for the antihyperalgesic action of topical capsaicin cream in nerve injury-induced neuropathic pain in mice (Rashid et al., 2003) . However, it is not yet known whether an upregulation of VR1 might contribute to the neuropathic pain in diabetes. Kamei et al. (2001) showed that intrathecal injection of anti-VR1 serum blocked the thermal and mechanical hyperalgesia observed in diabetic mice, suggesting the involvement of this receptor in diabetic neuropathic pain. In the present study, for the first time, we reported an upregulation of VR1 expression on myelinated primary afferent neurons of STZ-induced diabetic mice. We also showed that this upregulated VR1 on myelinated fibers might contribute to the antihyperalgesic action of topical capsaicin cream in diabetic neuropathic pain.
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Materials and Methods
Experimental animals: Male ddY mice were used throughout the experiments. They were housed in the animal facility of the University, which had been always maintained at 21 + 2 Û8Ã$$Ã+ 5 % relative humidity and an automatic 12-h light/dark cycle. The animals received standard laboratory diet (Oriental Yeast Co. Ltd., Japan) and tap water ad libitum.
The animals were adapted to the testing environment (maintained at 21 + 2 ÛC, 55 + 5 % relative humidity and 12-h light/dark cycle) by keeping them in the testing room 24 h before the experiments. Experiments were performed during the light phase of the cycle (10:00 -17:00). All procedures were approved by Nagasaki University Animal Care
Committee and complied with the recommendations of the International Association for the Study of Pain (Zimmerman 1983).
Drugs:
The following drugs were purchased, Substance P (SP; Peptide Institute, Osaka, Japan), adenosine triphosphate (ATP; Nacalai Tesque, Kyoto, Japan), capsaicin (Nacalai Tesque, Kyoto, Japan) and capsazepine (CPZ; Sigma, St. Louis, MO). ONO-54918-07 (a stable prostaglandin I 2 /PGI 2 agonist; Iguchi et al., 1989 ) was a kind gift from Ono Pharmaceutical Co. Ltd., Osaka, Japan. Capsaicin cream and base cream were prepared at the Central Research Laboratories of the Maruishi Pharmaceutical Co., Ltd., Osaka, Japan. The capsaicin cream labeled 0.01%, 0.025%, 0.05% and 0.1% contained 0.1, 0.25, 0.5 and 1 mg of capsaicin in 1 g of hydrophilic cream base respectively. The base cream contained 18% polyoxy-ethylated castor oil, 17% liquid paraffin, 5% white Vaseline, 4% 1-hexadecanol, 0.1% EDTA disodium salt, and 0.75% triethanolamine (Minami et al., 2001 ). All drugs except capsaicin and capsazepine were dissolved in physiological saline. JPET # 050948 8 physiological saline (5 mg/ml stock solution), which were then diluted with physiological saline before injection. This vehicle was found to be innocuous. The cream was applied in a volume of 0.1 ml /10 g and then gently rubbed over the mouse footpad skin 3 h before the behavioral test. The footpad was covered with adhesive tape to prevent the mice from licking up the cream.
STZ-induced diabetes:
The pancreatic β-cell cytotoxic agent streptozotocin (STZ) is widely used to induce diabetes in rodents. The glucosamine-nitrosourea compound STZ is taken up into the insulin-producing β-cells of the islets of Langerhan's via the GLUT-2 glucose transporter. The cytotoxic effect of STZ is mediated through a decrease in NAD levels, and the formation of intracellular free radicals leading to various toxic effects including DNA-strand breaks (Schnedl et al., 1994) . The STZ-induced diabetic rodents are hypoinsulinemic, but generally do not require exogenous insulin treatment to survive.
STZ-induced diabetic rodents show common features of human diabetes that include damage to the eye, kidney, blood vessels and nervous system. Diabetic neuropathic pain occurs mainly due to the damage in the nervous system (Sima and Sugimoto 1999) . In the present study, diabetes was induced in mice by a single intravenous (i.v.) injection of STZ (200 mg/kg, Wako Pure Chemicals, Richmond, VA) as reported previously (Kamei et al., 1991; Rashid and Ueda 2002) . Mice weighing ~30 g were injected i.v. with STZ in the tail vein. STZ solution was prepared freshly by dissolving it in saline adjusted to pH 4.5 in 0.1 N citrate buffer. Age-matched non-diabetic control mice were injected with the vehicle alone. Due to frequent urination (polyuria) in the diabetic mice, special care is needed for these animals. The STZ-injected mice were kept in a group of 4 per cage. The bed of the cage was changed daily and special attention was paid for food and water supplement. The plasma glucose level in the mice was measured using the 'glucose test kit' (Wako Pure Chemicals, Osaka, Japan) in blood samples obtained from tail vein. Only mice with a plasma glucose concentration greater than 300 mg/dl (16.7 mmol/L) were considered as diabetic. All efforts were made to minimize both the sufferings and number of animals used.
Thermal and mechanical nociception tests:
In the thermal paw withdrawal test, antinociception or analgesia was measured from the latency to withdrawal evoked by exposing the right hind paw to a thermal stimulus (Hargreaves et al., 1988) .
Unanesthetized animals were placed in Plexiglas cages on top of a glass sheet and an adaptation period of one hour was allowed. The thermal stimulus (IITC Inc., Woodland Hills, CA, USA) was positioned under the glass sheet to focus the projection bulb exactly on the middle of plantar surface of the animals. A mirror attached to the stimulus permitted visualization of the undersurface of the paw. A cut-off time of 20 seconds was set in order to prevent tissue damage. The paw pressure test was performed as described previously (Rashid and Ueda 2002) . Briefly, mice were placed into a Plexiglas chamber on a 6 6 mm wire mesh grid floor and were allowed to accommodate for a period of one hour. The mechanical stimulus was then delivered onto the middle of the plantar surface of the right hind-paw using a Transducer Indicator (Model 1601, IITC Inc., Woodland Hills, USA). With this apparatus, a control response of 10 g was earlier adjusted for naïve mice. A cut-off pressure of 20 g was set to avoid tissue damage. has been found to be less stressful and more sensitive than many conventional nociception tests (Inoue et al., 2003 in press).
Algogenic-induced nociceptive flexion (ANF) test:
Capsaicin-induced biting and licking test:
The biting and licking behavior after intraplantar injection of capsaicin solution (0.4 µg/20 µl) was measured as described previously by other investigators (Sakurada et al., 1992) . Mice were placed in a Plexiglas cage for an hour to adapt the environment. Before the test, mice were restrained in hand and gently taken inside a hard paper tube of internal diameter 2.5 cm. The right hindpaw was taken out of the tube and capsaicin was injected under the plantar surface of right Statistical analyses of all other data were performed using one-way ANOVA followed by a two-tailed Student's t-test. All data were presented as mean + SEM. P values less than 0.05 were considered to indicate statistical significance.
This article has not been copyedited and formatted. The final version may differ from this version. administration. Blood glucose levels in the STZ-injected mice were almost similar at all later time points tested (7, 14, 21, and 28 days after STZ injection). Similarly, thermal and mechanical hyperalgesia persisted in the diabetic animals at all these time points (Table 1) .
The blood glucose level, thermal latency and mechanical threshold did not differ significantly in the vehicle-treated control mice at all time points tested (data not shown).
The rate of increase in the body weight of STZ-treated mice was much slower than the vehicle-treated control mice. The body weight of control non-diabetic mice at 7, 14, 21
and 28 days were 108.8%, 123.7%, 130.8% and 135.9% of the initial weight respectively while they were 104.4%, 106.4%, 111.6% and 107.5% of initial weight respectively in case of diabetic mice. The body weight of the STZ-treated mice started to decline at 28 days after STZ injection. In an effort to minimize animal sufferings, we used mice at 7 days post-STZ injection in the following behavioral experiments.
Reversal of thermal and mechanical hyperalgesia in diabetic mice by capsaicin
This article has not been copyedited and formatted. The final version may differ from this version. . Very recently, we reported the peripheral nerve injury-induced phenotypic changes in the above three types of nociceptors and the effects of capsaicin cream thereon (Rashid et al., 2003) . In the present study, we also found phenotypic changes in these (Fig. 5B,C) . The level of increase in VR1 expression on myelinated fibers was almost similar in the DRGs of diabetic mice at 7, 14, 21 and 28 days after STZ injection (Fig. 5B ,C,G; 14 and 21 days data are not shown). Moreover, VR1 expression in unmyelinated C-fibers was not significantly increased in the diabetic mice (Fig. 5B,C) . In neonatal capsaicin-treated control mice, the VR1-immunoreactive neurons almost completely disappeared (Fig. 5D ). However, in neonatal capsaicin-treated diabetic mice, large numbers of VR1-immunoreactive neurons were observed in the DRGs which were colocalized with N-52 confirming the upregulation of VR1 expression on myelinated, neonatal capsaicin-insensitive fibers due to diabetes ( 18 colocalized with N-52 was observed in the diabetic mice (Fig. 5G ).
Discussion
In the present report, we attempted to identify whether an upregulation of vanilloid receptor subtype 1 (VR1) expression on myelinated fibers contributed to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice.
Intravenous (i.v.) injection of streptozotocin (STZ) in the tail vein of mice induced a rapid onset of hyperglycemia within 24 h, and significant thermal and mechanical hyperalgesia was detectable by 3 days after STZ injection (Table 1) (Fig. 1A,B) . Capsaicin, the active ingredient of capsaicin cream, gives its analgesic effect by desensitizing the capsaicin receptor (Jancsó and Jancsó 1949; Holzer 1991; Szallasi and Blumberg 1999) .
Thus an upregulation and/or sensitization of the capsaicin receptor could be speculated in the STZ-induced diabetic mice.
With the algogenic-induced nociceptive flexion (ANF) test, we recently reported that capsaicin cream could block the nociceptive responses mediated through neonatal capsaicin-sensitive type I and type II, but not neonatal capsaicin-insensitive type III, fibers in naïve mice (Rashid et al., 2003 (Rashid et al., 2003) . In the present study, the substance P-induced nociceptive response, which is mediated through type I fibers, and the ATP-induced nociceptive response, which is mediated through type II fibers, did not differ between the non-diabetic and diabetic mice ( Fig.   2A,B) . However, the PGI 2 agonist-induced nociceptive response, which is mediated through type III fibers, was hypersensitized in the diabetic mice compared with the control mice (Fig. 2C) . The contrasting phenotypic change in type I responses in partial sciatic nerve-injured and diabetic mice might be due to the intense mechanical injury to the sciatic nerve and consequent drastic changes including decrease in SP-immunoreactivity in DRG and spinal cord with the injury model Lee et al., 2001 ). On the other hand, similar to the case with nerve injury model, capsaicin cream concentration-dependently reversed the PGI 2 agonist-induced type III fiber-mediated hyperalgesia in diabetic mice (Fig. 3) . Thus, the induction of PGI 2 agonist-induced hyperalgesia in diabetic mice could be due to an upregulated capsaicin indicating an increase in capsaicin-sensitive sites due to diabetes (Fig. 4A) . Moreover, after neonatal capsaicin treatment in mice, which destroys most unmyelinated C-fibers, the i.pl. capsaicin-induced biting-licking responses almost completely disappeared indicating that capsaicin-induced biting-licking responses in control mice were mainly mediated through the C-fibers (Fig. 4B ). This finding is consistent with the fact that capsaicin receptor VR1 is mainly expressed in the polymodal nociceptive C-fibers (Caterina et al., 1997) . In the neonatal capsaicin-treated diabetic mice, however, the i.pl.
capsaicin-induced biting-licking responses surprisingly reappeared (Fig. 4B ). This finding clearly indicates that STZ-induced diabetes in mice caused an upregulation of the capsaicin receptor on myelinated, neonatal capsaicin-insensitive type III fibers.
Furthermore, involvement of capsaicin receptor in the increased i.pl. capsaicin solution-induced responses in the diabetic mice was revealed by the fact that the competitive VR1 antagonist capsazepine completely blocked these responses (Fig. 4A,B ).
All these results suggest an increased expression of capsaicin receptor VR1 on previously capsaicin-insensitive type III fibers due to diabetes.
We next confirmed the upregulation of VR1 expression on myelinated, neonatal capsaicin-insensitive type III fibers due to diabetes by immunohistochemistry. Consistent with our previous report (Rashid et al., 2003) , almost all of the VR1-immunoreactive neurons in the DRG of control mice were not colocalized with the A-fiber marker N-52, indicating their presence on unmyelinated C-fibers in naïve state. In the STZ-induced diabetic mice, the VR1 expression significantly increased only on the myelinated A-fibers (Fig. 5B,C,G) . VR1-immunoreactive neurons in the DRGs of neonatal capsaicin treated mice almost completely disappeared, which is consistent with previous reports (Rashid et al., 2003; Mezey et al., 2000) . However, STZ-induced diabetes in neonatal with A-fiber marker N-52 (Fig. 5E,F) . These results confirmed our speculation that capsaicin cream reversed the hyperalgesia in diabetic mice (Fig. 1A,B and Direct activation of VR1 channel by protein kinase C has also been reported (Premkumar and Ahern 2000) . Thus, the upregulation of VR1 expression on myelinated fibers may contribute to the altered activities of these fibers as well to the maintenance of peripheral and central sensitization in neuropathy states.
In conclusion, we demonstrate that the thermal, mechanical and chemical hyperalgesia 'Control' is the paw withdrawal latency or threshold in vehicle-treated control non-diabetic mice. 
